scout
|Videos|November 15, 2017

Dr. Postow on Entrectinib in Melanoma

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of entrectinib for patients with NTRK fusion-positive melanoma.

Michael A. Postow, MD, medical oncologist, Memorial Sloan Kettering Cancer Center, discusses the role of entrectinib for patients with NTRK fusion-positive melanoma.

Following more comprehensive molecular profiling, there are different genetic fusion events or other types of activating mutations, states Postow. There is a new fusion that has been discovered around NTRK that affects patients with advanced melanoma.

There are some promising strategies being used to target NTRK fusion, such as entrectinib, Postow explains.

Newsletter

Stay up to date on the most recent and practice-changing oncology data


Latest CME